GLSIGreenwich Lifesciences, Inc.
Greenwich Lifesciences, Inc. (GLSI) develops immunotherapies for breast cancer, with its Phase III FLAMINGO-01 trial testing GLSI-100, a Fast Track-designated candidate. The next catalyst is Oct 15, 2026 — Anticipated Equity Financing Announcement, which will test whether the company can secure capital amid ongoing cash constraints. (Per )
- GLSI is a clinical-stage biopharmaceutical company with no commercial products.
- The company has reported net losses and negative free cash flow in recent quarters.
- Its Phase III trial is a key differentiator, but cash runway remains a critical risk.
The Read
GLSI’s stock has historically surged about 30% on solid Phase III FLAMINGO-01 trial progress and strong clinical data but plunged nearly 18% and 22% when failing to clarify cash runway and facing Nasdaq filing delays, with positive patent news briefly lifting shares about 3%.
The schedule
- Thu15Oct
The equity financing announcement will test investor sentiment around the company's capital structure and potential dilution. This event is critical for assessing the market's appetite for further fundraising and its implications on existing shareholders.
- Thu5Nov
The completion of Phase III patient enrollment for FLAMINGO-01 will be a key milestone for the company's pipeline. This event will test the market's confidence in the trial's feasibility and the company's ability to meet enrollment targets.
- Fri13Nov
The Q3 earnings release will provide insight into the company's financial performance, including revenue, expenses, and guidance for the future. This event will test the market's expectations for the quarter and the company's ability to meet or exceed them.
- Tue8Dec
The SABCS will provide an opportunity for the company to present its research and data on FLAMINGO-01. This event will test the market's perception of the company's scientific credibility and the potential impact of its findings.
- Wed6Jan
A competitor's clinical trial update could impact the market's perception of the company's competitive position. This event will test the market's reaction to any news that may affect the company's pipeline or market share.
- Sun14Feb
The Q4 earnings release will provide insight into the company's financial performance, including revenue, expenses, and guidance for the future. This event will test the market's expectations for the quarter and the company's ability to meet or exceed them.
- Thu15Apr
The pre-Phase III data positioning and strategic planning will test the market's confidence in the company's ability to prepare for the next phase of its clinical trials. This event will also provide insight into the company's strategic direction and potential for future growth.
- Fri7May
The Q1 earnings release will provide insight into the company's financial performance, including revenue, expenses, and guidance for the future. This event will test the market's expectations for the quarter and the company's ability to meet or exceed them.
- Fri13Aug
The Q2 earnings release will provide insight into the company's financial performance, including revenue, expenses, and guidance for the future. This event will test the market's expectations for the quarter and the company's ability to meet or exceed them.
Past
- Fri14Aug
Actual outcome: Bear · $17.61 at outcome
GLSI reported EPS of -0.39, matching expectations, and provided an update on the FLAMINGO-01 project, highlighting progress in scaling production and improving efficiency. The stock fell despite the earnings beat due to weaker-than-expected revenue guidance and concerns about margin pressures, which overshadowed the positive project update.
Quarterly earnings print highlighting cash runway and patient screening rates for the Phase 3 trial.
- Thu4Jun
Actual outcome: Mixed · $24.06 at outcome
Greenwich LifeSciences reported in-line EPS of -$0.39 and presented open-label data from its FLAMINGO-01 Phase III trial at the ASCO meeting. The stock saw a muted 1.6% reaction by the outcome date, as the expected earnings and clinical updates lacked the definitive cash runway or financing visibility needed to drive a significant breakout.
Q1 2026 earnings will refocus investors on GLSI’s cash burn and the remaining runway to complete the FLAMINGO-01 Phase III trial. A clear plan to extend cash—via a concrete financing or partnership path—alongside steady enrollment could support a move toward $26.00, while another vague runway update without funding visibility risks a break toward $26.00 as dilution fears intensify.
- Tue7Apr
Actual outcome: Bull · $25.78 at outcome
Greenwich LifeSciences announced positive open-label data from its Phase 3 FLAMINGO-01 trial showing an 80% recurrence reduction, along with new patent claims that could double the GP2 market potential. These strong clinical and intellectual property updates overshadowed prior concerns regarding an imminent capital raise, driving bullish sentiment and pushing the stock near the $25.00 bull target.
Imminent capital raise to address the critically low cash runway ($3.8M) identified in the Q4 2025 update.
- Tue3Mar
Actual outcome: Bear · $24.67 at outcome
While Greenwich LifeSciences met EPS estimates and reported increased patient screening rates for its Phase III FLAMINGO-01 trial, the company failed to provide a definitive solution for its critically low cash position. This lack of a clear funding runway confirmed market fears of imminent and significant shareholder dilution, driving the stock price below the $25.00 bear floor as investors prioritized liquidity risks over incremental clinical updates.
The Q3 2025 cash balance was critically low ($3.8M) relative to the cash burn rate. The market anticipates the Q4 report will confirm the need for an immediate capital raise, leading to significant downward pressure from dilution fears.